Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | A targeted treatment with anti-CD19 CAR T-cells results in different responses

David Maloney, MD, PhD, from Seattle Cancer Care Alliance, USA gives an overview of the anti-CD19 CAR T-cell trial (NCT01865617) at the European Haematological Association (EHA) 2017 in Madrid, Spain. Dr Maloney explains that the trial included all CD 19+ve malignancies including acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). He explains how despite these malignancies being CD19 positive, they all responded to the T cell treatment differently.